Compare CABO & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CABO | PALI |
|---|---|---|
| Founded | 1980 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 425.5M | 359.7M |
| IPO Year | 2015 | 2019 |
| Metric | CABO | PALI |
|---|---|---|
| Price | $21.61 | $2.03 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $125.67 | $11.29 |
| AVG Volume (30 Days) | 271.6K | ★ 1.7M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 97.06 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,501,423,000.00 | $260,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.83 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1500.39 |
| 52 Week Low | $20.72 | $0.55 |
| 52 Week High | $180.74 | $2.86 |
| Indicator | CABO | PALI |
|---|---|---|
| Relative Strength Index (RSI) | 37.48 | 49.23 |
| Support Level | N/A | $1.93 |
| Resistance Level | $29.39 | $2.17 |
| Average True Range (ATR) | 3.19 | 0.10 |
| MACD | 0.10 | -0.00 |
| Stochastic Oscillator | 10.60 | 37.50 |
Cable One Inc is a telecommunications company that generates revenue from providing broadband, voice, and video services to both residential and business customers. The company derives majority of its revenue from data and video services, which are subscription-based and billed monthly. The company also offers Sparklight TV, an Internet Protocol Television (IPTV) service that enables customers using the Sparklight TV app to stream video channels from the cloud. Additionally, the company earns advertising revenue by selling airtime on its video channels, and it provides voice services over Internet protocols.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.